Mexico's government awarded at least three contracts worth up to 227 million pesos (approximately $12 million) in 2025 to a company linked to Cuba's state-run pharmaceutical sector to purchase cancer medications, according to a report by Mexican outlet Latinus, raising questions about the country's commercial ties with Havana as officials continue to frame broader cooperation as humanitarian.
The contracts were granted to Neuronic Mexicana S.A. de C.V., a firm tied to BioCubaFarma, a conglomerate created by Cuba's Council of Ministers. The agreements include the acquisition of drugs such as vincristine, methotrexate and doxorubicin, used in chemotherapy treatments for conditions including leukemia and lymphomas.
